Skip to main content
Premium Trial:

Request an Annual Quote

Good-Bye to Theranos

Blood-testing firm Theranos is shutting down, the Wall Street Journal reports.

At its height, Theranos was valued at more than $9 billion, the Journal notes. But its claims that it could conduct a number of lab tests using a small amount of blood, began to collapse following a series of articles in the Journal that indicated the company's technology and lab practices might not be all they were cracked up to be. In early 2016, the Centers for Medicare & Medicaid Services sent the firm a letter about deficiencies in its lab testing procedures and then barred Theranos founder Elizabeth Holmes from owning or operating a lab for two years.

Holmes has since been indicted by a US federal grand jury alongside former company president Ramesh Balwani for wire fraud, with prosecutors claiming they defrauded both investors and doctors. Holmes and Balwani pleaded not guilty.

And now, the Journal reports, the company is formally dissolving. This comes, it adds, after a failed attempt to sell the company. As 360Dx reports, Theranos is in default of its credit facility with the Fortress Investment Group and owes unsecured creditors about $60 million. It adds that the firm is negotiating a settlement with Fortress.

Most of Theranos employees had their last day August 31, the Journal adds.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.